Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and
progressive tumors from endocrine system.
The primary objective is to assess the efficacy of cabozantinib plus atezolizumab combination
by means of radiological objective response rate (ORR) evaluated following RECIST v1.1
criteria in advanced endocrine tumors.
Endocrine tumors from different origins (thyroid, lung, pancreas and digestive tract, adrenal
gland and paraganglia) are characterized by being remarkably vascular and expressing several
growth factors including vascular endothelial growth factor (VEGF), platelet-derived growth
factor (PDGF), insulin-like growth factor 1 (IGF-1), basic fibroblast growth factor (BFGF),
and transforming growth factor (TGF)-α and -β. The (over) expression of some of these factors
has been linked to poor prognosis. Cabozaninib, a VEGF inhibitor, in combination with
atezolizumab, an inhibitor of PD-L1, may be active in endocrine tumors by overcoming the
resistance to prior antiangiogenic drugs.
The trial will include patients with advanced and refractory tumors of endocrine system and
patients would be allocated to six different cohorts according to the following tumor types.